Guardant Health
GH
Performance
About Guardant Health
Guardant Health is a leading precision medicine company focused on transforming cancer care through blood-based diagnostics and data. The company develops and commercializes liquid biopsy tests that inform treatment decisions across screening, early detection, and advanced cancer management, with a global presence including its headquarters in Palo Alto, California. Its portfolio includes Shield blood tests, Guardant Complete, and Guardant Infinity, and it collaborates with clinicians, researchers, and biopharma partners to advance precision oncology and biomarker-driven therapies.
Recent News
FDA Clears FoundationOne CDx as Companion Diagnostic for Tepotinib in MET‑Exon‑14 NSCLC
Guardant's Shield Test Added to American Cancer Society Colorectal Screening Guidelines
Assessing the Roche Acquisition of SAGA Diagnostics and the Future of Molecular Residual Disease Monitoring
TOBY Gets FDA Breakthrough Device Designation for Urine-Based Multi-Cancer Test
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
The Marketing Guru Who Helped Turn Khosla Ventures Into an AI Powerhouse Is Moving On
Jimini Health Secures $17M to Scale Clinician-Supervised Behavioral Health AI
Labcorp Expands Epic Pact to Make Full Test Menu Available on Aura
Drug Digest: Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
Q32 Bio Raises $55M as Guardant, Soligenix, Novavax Lead Biotech Gains
Exaforce Raises $125M Series B to Build AI for Catching and Stopping Cyberattacks as They Happen
Guardant Health Q1 Revenue Surges 48% YoY to $302M, Fastest Growth in Five Years
Evercore ISI Keeps an “In Line” Rating on Guardant Health, Inc. (GH)
Quest Diagnostics Inc (DGX) Q1 2026 Earnings Call Transcript